Medical Journals

  • Publications

    Building AI with
    strong scientific
    evidence

  • Oncology

    Abstract : Deep learning-based H&E analyzer reveals distinct immune profiles and clinical outcomes among immune phenotypes in uterine corpus endometrial carcinoma

    AACR (2022) — Apr 10, 2022

    Horyun Choi et al.

  • Oncology

    Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals immune-excluded phenotype is correlated with TGF-beta pathway related genomic aberrations

    AACR (2022) — Apr 8, 2022

    Gahee Park, et al.

  • Breast

    Mammographically occult breast cancers detected with AI-based diagnosis supporting software: clinical and histopathologic characteristics

    Insights into Imaging (2022) — Mar 26, 2022

    Hee Jeong Kim et al.

  • Oncology

    Abstract : Artificial Intelligence-Powered Tumor Purity Assessment From H&E Whole Slide Images Correlates...

    USCAP (2022) — Mar 22, 2022

    Gahee Park et al.


Research Collaborations


Lunit AI in Medical Journals

All
AI
Breast
Chest
  • Oncology

    Need of pretreatment support of breast cancer patient caregivers compared to patients.

    ASCO(2022) — May 27, 2022

    Terri Kim et al.

  • Oncology

    Robust artificial intelligence-powered imaging biomarker based on mammography for risk prediction of breast cancer.

    ASCO(2022) — May 27, 2022

    Eun Kyung Park et al.

  • Oncology

    Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: a phase I study

    ASCO(2022) — May 27, 2022

    Do-Youn Oh et al.

  • Oncology

    Tumor-infiltrating lymphocyte enrichment predicted by CT radiomic analysis is associated with clinical outcomes of immune checkpoint inhibitor in non-small cell lung cancer

    ASCO(2022) — May 27, 2022

    Changhee Park et al.

  • Oncology

    The Inflamed Immune Phenotype (IIP): a clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types

    ASCO(2022) — May 27, 2022

    Jeanne Shen et al.

  • Oncology

    Trastuzumab plus FOLFOX for Gemcitabine/Cisplatin refractory HER2-positive biliary tract cancer: a multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)

    ASCO(2022) — May 27, 2022

    Choong-kun Lee et al.

  • Oncology

    Artificial intelligence (AI)-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes

    ASCO(2022) — May 27, 2022

    Gahee Park et al.

  • Oncology

    Artificial Intelligence (AI) - powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple negative breast cancer (TNBC)

    ASCO(2022) — May 27, 2022

    Hee Jin Lee et al.